News

0

Stolmár & Partner successfully secures EMA Orphan Drug Designation for the Treatment of amyotrophic lateral sclerosis (ALS) for Federal Institute of Technology (Ecole Polytechnique Fédérale ) Lausanne (EPFL), Switzerland.

Von Stolmár & Partner, (Kommentare: 0)

Stolmár & Partner is happy to announce that the European Medicines Agency (EMA) has granted orphan drug designation (EU/3/18/2008) on 16 April 2018 to Adeno-associated viral vector serotype 9 encoding miRNA against human superoxide dismutase 1 for the treatment of amyotrophic lateral sclerosis for its client Ecole Polytechnique Fédérale Lausanne (EPFL), Switzerland, where S & P acted as EU sponsor.

Weiterlesen …

0

IAM Patent 1000 lists Paul-Alexander Wacker among recommended patent experts

Von Stolmár & Partner, (Kommentare: 0)

Yesterday, Intellectual Asset Management magazine publicly released its 2018 rankings of the IAM Patent 1000, listing Paul-Alexander Wacker among this distinguished class.

Paul-Alexander Wacker has been listed for several consecutive years among the IAM 1000. He now continues his appearance in the listings as of-counsel of Stolmár & Partner.

The IAM Patent 1000 provides a resource for identifying world-class patent attorneys in private practice. The quantitatively-evaluated listings account for depth of knowledge, market presence, level of work, and positive peer and client feedback.

For more information, please see Paul-Alexander Wacker’s  full profile on the IAM 1000 website.

Weiterlesen …

0

Dr. Matthias Stolmár publizierte in Biospektrum 03 2018 einen Artikel über den Widerruf des CRISPR/CAS Grundlagenpatents EP 2 771 468 B1 des Broad Instituts vor dem Europäischen Patentamt.

Von Stolmár & Partner, (Kommentare: 0)

Zu lesen unter:

https://www.biospektrum.de/blatt/d_bs_pdf&_id=1564662

Weiterlesen …